Jun. 25 at 2:14 AM
$KALV recent dip in KALV was triggered by behind-the-scenes turmoil at the FDA. Reports surfaced that the new Commissioner, Marty Makary, tried to force a rejection (CRL) of KalVista’s drug, despite it being in active review. This caused uncertainty and likely leaked, spooking investors.
But here’s the key: senior FDA scientists pushed back, citing legal and scientific concerns, and the rejection never went through. The fact that internal FDA staff stood their ground and defended the review process is a strong bullish signal.
The stock bounced back once the news got out that the attempted interference failed—and the drug is still under review with no known safety or efficacy issues. That makes this whole event a shakeout, not a setback.
Bottom line: The dip was fear-driven. The bounce shows the market realized the fundamentals didn’t change. If anything, this proves how close KALV is to approval—and how strong the internal support is behind it.
